Zika virus: Novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase

Future Virology

Volumn 12, Issue 12, 2017, Pages 721-728

  Elfiky, Abdo A ^a,b  

^a CAIRO UNIVERSITY   (Egypt)

^b ABDUS SALAM INTERNATIONAL CENTRE FOR THEORETICAL PHYSICS   (Italy)

Author keywords

guanosine derivatives; molecular modeling; polymerase; protein ligand docking; zika virus

Indexed keywords

ANTIVIRUS AGENT; GUANOSINE DERIVATIVE; GUANOSINE TRIPHOSPHATE; IDX 184; RIBAVIRIN; RIBOSE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS POLYMERASE;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; ZIKA VIRUS;

EID: 85034063406     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl-2017-0081     Document Type: Article

References (42)

1. Lanciotti RS, Kosoy OL, Laven JJ et al. Genetic and serologic properties of zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14(8), 1232-1239 (2008).
2. Haddow AD, Schuh AJ, Yasuda CY et al. Genetic characterization of zika virus strains: geographic expansion of the Asian lineage. PLoS Negl. Trop. Dis. 6(2), e1477 (2012).
3. Dick GWA, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46(5), 509-520 (1952).
4. Zumla A, Goodfellow I, Kasolo F et al. Zika virus outbreak and the case for building effective and sustainable rapid diagnostics laboratory capacity globally. Int. J. Infect. Dis. 45, 92-94 (2016).
5. Wu S, Skolnick J, Zhang Y. Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol. 5(17), 10 (2007).
6. MacNamara FN. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans. R. Soc. Trop. Med. Hyg. 48(2), 139-145 (1954).
7. Zumla A, Goodfellow I, Kasolo F et al. Zika virus outbreak and the case for building effective and sustainable rapid diagnostics laboratory capacity globally. Int. J. Infect. Dis. 45, 92-94 (2016).
8. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging zika virus in the Pacific area. Clin. Microbiol. Infect. 20(10), O595-O596 (2014).
9. Duffy MR, Chen TH, Hancock WT et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N. Engl. J. Med. 360(24), 2536-2543 (2009).
10. Haddow AJ, Williams MC, Woodall JP, Simpson DI, Goma LK. Twelve isolations of zika virus from Aedes (stegomyla) africanus (theobald) taken in and above a Uganda forest. Bull. World Health Organ. 31(57), 57-69 (1964).
11. Boorman JPT, Porterfield JS. A simple technique for infection of mosquitoes with viruses transmission of zika virus. Trans. R. Soc. Trop. Med. Hyg. 50(3), 238-242 (1956).
12. Grard G, Caron M, Mombo IM et al. Zika virus in Gabon (Central Africa)-2007: a new threat from Aedes albopictus? PLoS Negl. Trop. Dis. 8(2), e2681 (2014).
13. Tauro LB, Bandeira AC, Ribeiro GS et al. Potential use of saliva samples to diagnose zika virus infection. J. Med. Virol. 89(1), 1-2 (2017).
14. Musso D, Rouault E, Teissier A et al. Molecular detection of zika virus in blood and RNA load determination during the French Polynesian outbreak. J. Med. Virol. 89(9), 1505-1510 (2017).
15. Olson JG, Ksiazek TG, Suhandiman, Triwibowo. Zika virus, a cause of fever in Central Java, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 75(3), 389-393 (1981).
16. Mlakar J, Korva M, Tul N et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374(10), 951-958 (2016).
17. Zika Strategic Response Framework and Joint Operations Plan, January-June 2016. WHO, Geneva, Switzerland (2016).
18. Kuno G, Chang GJ. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and zika viruses. Arch. Virol. 152(4), 687-696 (2007).
19. Upadhyay AK, Cyr M, Longenecker K, Tripathi R, Sun C, Kempf DJ. Crystal structure of full-length zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5. Acta. Crystallogr. F. Struct. Biol. Commun. 73(3), 116-122 (2017).
20. Lemon SM, Mckeating JA, Pietschmann T et al. Development of novel therapies for hepatitis C. Antiviral Res. 86(1), 79-92 (2010).
21. Elfiky AA, Elshemey WM, Gawad WA. 2-methylguanosine prodrug (IDX-184), phosphoramidate prodrug (sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study. J. Comput. Theor. Nanosci. 12(3), 376-386 (2015).
22. Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J. Med. Virol. 89(6), 1040-1047 (2017).
23. Das D, Hong J, Chen SHet al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorg. Med. Chem. 19(16), 4690-4703 (2011).
24. De Francesco R, Carfí A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev. 59(12), 1242-1262 (2007).
25. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 58(1), 1-16 (2003).
26. Gonzalez-Grande R, Jimenez-Perez M, Gonzalez Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J. Gastroenterol. 22(4), 1421-1432 (2016).
27. Asselah T. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J. Hepatol. 61(2), 435-438 (2014).
28. Elfiky AA, Elshemey WM, Gawad WA, Desoky OS. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 32(1), 75-80 (2013).
29. Beaulieu PL, Gillard J, Jolicoeur E et al. From benzimidazole to indole-5-carboxamide thumb pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons. Bioorg. Med. Chem. Lett. 21(12), 3658-3663 (2011).
30. Saleh NA, Elfiky AA, Ezat AA, Elshemey WM, Ibrahim M. The electronic and quantitative structure activity relationship properties of modified telaprevir compounds as HCV NS3 protease inhibitors. J. Comput. Theor. Nanosci. 11(2), 544-548 (2014).
31. Bullard-Feibelman KM, Govero J, Zhu Z et al. The FDA-approved drug sofosbuvir inhibits zika virus infection. Antiviral Res. 137, 134-140 (2017).
32. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 1(6), 607-616 (2011).
33. Tong J, Wang YW, Lu YA. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J. Zhejiang Univ. Sci. B 13(1), 56-82 (2012).
34. Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J. Med. Virol. 88, 2044-2051 (2016).
35. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protocols 10(6), 845-858 (2015).
36. Summers KL, Mahrok AK, Dryden MD, Stillman MJ. Structural properties of metal-free apometallothioneins. Biochem. Biophys. Res. Commun. 425(2), 485-492 (2012).
37. Lii JH, Allinger NL. Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons. J. Am. Chem. Soc. 111(23), 8576-8582 (1989).
38. Stewart JJP. Optimization of parameters for semiempirical methods. III. Extension of PM3 to Be, Mg, Zn, Ga, Ge, As, Se, Cd, In, Sn, Sb, Te, Hg, Tl, Pb, and Bi. J. Comp. Chem. 12(3), 320-341 (1991).
39. Becke AD. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 98(7), 5648-5652 (1993).
40. Muegge I. A knowledge-based scoring function for protein-ligand interactions: probing the reference state. In: Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop 'New Approaches in Drug Design and Discovery', Special Topic 'Virtual Screening', Schlo? Rauischholzhausen, Germany, March 15-18, 1999. Klebe G (Ed.). Springer, Dordrecht, The Netherlands, 99-114 (2002).
41. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comp. Chem. 31(2), 455-461 (2010).
42. Wang B, Tan XF, Thurmond S et al. The structure of zika virus NS5 reveals a conserved domain conformation. Nat. Commun. 8, 14763 (2017).